New Results

The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory

Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, Henri Estanbouli, Aurélie Bouteau, Botond Z. Igyártó
doi: https://doi.org/10.1101/2021.03.04.430128

Article Information

doi 
https://doi.org/10.1101/2021.03.04.430128
History 
  • July 23, 2021.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Sonia Ndeupen1,
  2. Zhen Qin1,
  3. Sonya Jacobsen1,
  4. Henri Estanbouli1,
  5. Aurélie Bouteau1 and
  6. Botond Z. Igyártó1,*
  1. 1Thomas Jefferson University, Department of Microbiology and Immunology, Philadelphia, PA
  1. ↵*Address correspondence to: Botond Z. Igyártó, Email: botond.igyarto{at}jefferson.edu
Back to top
Posted July 23, 2021.
Download PDF

Supplementary Material

Email
The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, Henri Estanbouli, Aurélie Bouteau, Botond Z. Igyártó
bioRxiv 2021.03.04.430128; doi: https://doi.org/10.1101/2021.03.04.430128
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area